GSK PLC Sponsored ADR $GSK Shares Acquired by Acadian Asset Management LLC

Key Points

• Acadian Asset Management LLC increased its holdings in GSK PLC Sponsored ADR by 201.9%, acquiring an additional 2,663,270 shares, bringing its total to nearly 4 million shares valued at approximately $154 million.
• GSK reported a quarterly earnings per share of **$1.23**, exceeding forecasts and demonstrating a revenue increase to **$10.64 billion**, which is a year-over-year growth of 1.3%.
• GSK recently declared a quarterly dividend of **$0.4206** per share, resulting in an annualized yield of **4.2%**, despite a reported dividend payout ratio of 77.78%.

Acadian Asset Management LLC increased its stake in shares of GSK PLC Sponsored ADR (NYSE:GSK - Free Report) by 201.9% in the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,982,324 shares of the pharmaceutical company's stock after purchasing an additional 2,663,270 shares during the quarter. Acadian Asset Management LLC owned approximately 0.19% of GSK worth $154,244,000 at the end of the most recent reporting period.

A number of other institutional investors also recently modified their holdings of the company. Dodge & Cox boosted its stake in shares of GSK by 14.9% in the 1st quarter. Dodge & Cox now owns 78,651,833 shares of the pharmaceutical company's stock valued at $3,046,972,000 after purchasing an additional 10,210,921 shares during the last quarter. Primecap Management Co. CA grew its position in GSK by 1.8% during the first quarter. Primecap Management Co. CA now owns 25,708,020 shares of the pharmaceutical company's stock valued at $995,929,000 after buying an additional 446,360 shares during the period. Price T Rowe Associates Inc. MD boosted its position in GSK by 2.1% during the first quarter. Price T Rowe Associates Inc. MD now owns 7,722,314 shares of the pharmaceutical company's stock worth $299,163,000 after purchasing an additional 155,392 shares during the period. Royal Bank of Canada lifted its holdings in shares of GSK by 5.7% in the first quarter. Royal Bank of Canada now owns 7,581,079 shares of the pharmaceutical company's stock worth $293,692,000 after buying an additional 411,869 shares in the last quarter. Finally, Equity Investment Corp lifted its holdings in shares of GSK by 5.3% in the first quarter. Equity Investment Corp now owns 4,174,189 shares of the pharmaceutical company's stock worth $161,708,000 after buying an additional 211,608 shares in the last quarter. 15.74% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several research analysts have commented on the stock. Berenberg Bank reissued a "hold" rating on shares of GSK in a research note on Tuesday, June 3rd. Wall Street Zen upgraded shares of GSK from a "buy" rating to a "strong-buy" rating in a research note on Friday, September 5th. Six analysts have rated the stock with a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat, GSK currently has an average rating of "Reduce" and an average price target of $37.38.

GSK Stock Down 1.6%

Shares of GSK traded down $0.67 during midday trading on Friday, reaching $40.81. 4,741,956 shares of the stock were exchanged, compared to its average volume of 3,553,270. GSK PLC Sponsored ADR has a 52 week low of $31.72 and a 52 week high of $43.62. The company has a current ratio of 0.87, a quick ratio of 0.57 and a debt-to-equity ratio of 1.07. The company's 50 day moving average is $38.74 and its two-hundred day moving average is $38.46. The company has a market capitalization of $83.12 billion, a P/E ratio of 18.89, a PEG ratio of 2.07 and a beta of 0.53.

GSK (NYSE:GSK - Get Free Report) last issued its quarterly earnings data on Wednesday, July 30th. The pharmaceutical company reported $1.23 earnings per share for the quarter, beating analysts' consensus estimates of $1.12 by $0.11. GSK had a return on equity of 49.22% and a net margin of 10.81%.The company had revenue of $10.64 billion for the quarter, compared to the consensus estimate of $7.92 billion. During the same quarter last year, the company earned $0.43 earnings per share. The firm's revenue for the quarter was up 1.3% compared to the same quarter last year. GSK has set its FY 2025 guidance at 4.590-4.590 EPS. On average, sell-side analysts anticipate that GSK PLC Sponsored ADR will post 4.14 earnings per share for the current year.

GSK Cuts Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 9th. Investors of record on Friday, August 15th will be paid a $0.4206 dividend. This represents a $1.68 annualized dividend and a yield of 4.1%. The ex-dividend date of this dividend is Friday, August 15th. GSK's dividend payout ratio is currently 77.78%.

GSK Profile

GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through two segments, Commercial Operations and Total R&D.